Pyxis Oncology announces FDA clearance of two IND applications

Pyxis Oncology announced that it has received clearance for its two Investigational New Drug applications from the U.S. FDA to initiate Phase 1 clinical trials. PYX-201, a novel antibody-drug conjugate product candidate, will be investigated for the potential treatment of several solid tumors, including breast, head and neck, lung, and thyroid cancer. PYX-106, an immunotherapy product candidate, will be investigated for the potential treatment of solid tumors, including bladder, cholangio-carcinoma, colorectal, and kidney cancer. Trials are expected to begin in early 2023.